Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/72485 |
Resumo: | Heparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs. |
id |
RCAP_f53088df8a424f3c24cecbe269c9afdb |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/72485 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systemsHeparinAnticoagulant drugsDrug delivery systemsAnticoagulant assaysHeparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs.This work was supported by the Banco do Nordeste (grant FUNDECI/2016.0015), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de Sergipe (Fapitec), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). Eliana B. Souto would like to acknowledge the Portuguese Science and Technology Foundation (FCT/MCT) and the European Funds (PRODER/COMPETE) for the project UIDB/04469/2020 (strategic fund), co-financed by FEDER, under the Partnership Agreement PT2020.info:eu-repo/semantics/publishedVersionMDPIUniversidade do MinhoPatriota, Yuri B. G.Chaves, Luíse L.Gocke, Evren H.Severino, PatriciaSoares, Mônica F. R.Soares-Sobrinho, José L.Souto, Eliana B.2021-052021-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/72485engPatriota, Yuri B. G.; Chaves, Luíse L.; Gocke, Evren H.; Severino, Patricia; Soares, Mônica F. R.; Soares-Sobrinho, José L.; Souto, Eliana, Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems. Applied Nano, 2(2), 98-117, 20212673-350110.3390/applnano2020009https://www.mdpi.com/2673-3501/2/2/9info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:13:13Zoai:repositorium.sdum.uminho.pt:1822/72485Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:05:16.287487Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
title |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
spellingShingle |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems Patriota, Yuri B. G. Heparin Anticoagulant drugs Drug delivery systems Anticoagulant assays |
title_short |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
title_full |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
title_fullStr |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
title_full_unstemmed |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
title_sort |
Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems |
author |
Patriota, Yuri B. G. |
author_facet |
Patriota, Yuri B. G. Chaves, Luíse L. Gocke, Evren H. Severino, Patricia Soares, Mônica F. R. Soares-Sobrinho, José L. Souto, Eliana B. |
author_role |
author |
author2 |
Chaves, Luíse L. Gocke, Evren H. Severino, Patricia Soares, Mônica F. R. Soares-Sobrinho, José L. Souto, Eliana B. |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Patriota, Yuri B. G. Chaves, Luíse L. Gocke, Evren H. Severino, Patricia Soares, Mônica F. R. Soares-Sobrinho, José L. Souto, Eliana B. |
dc.subject.por.fl_str_mv |
Heparin Anticoagulant drugs Drug delivery systems Anticoagulant assays |
topic |
Heparin Anticoagulant drugs Drug delivery systems Anticoagulant assays |
description |
Heparin-based delivery systems have been explored to improve their therapeutic efficacy and to reduce toxicity for different administration routes. Regardless of the applied drug delivery system (DDS), the evaluation of anticoagulant performance is instrumental for the development of a suitable DDS. The understanding of the range of anticoagulant assays, together with their key applications and limitations, is essential both within the context of scientific research and for clinical usage. This review provides an overview of the current anticoagulant therapy and discusses the advantages and limitations of currently available anticoagulant assays. We also discuss studies involving low-molecular-weight heparin (LMWH)-based nanocarriers with emphasis on their anticoagulation performance. Conventional anticoagulants have been used for decades for the treatment of many diseases. Direct oral anticoagulants have overcome some limitations of heparins and vitamin K antagonists. However, the lack of an accurate laboratory assessment, as well as the lack of a factor xaban (Xa) inhibitor reversal agent, remains a major problem associated with these anticoagulants. LMWHs represent anticoagulant agents with noteworthy efficacy and safety, and they have been explored to improve their outcomes with various nanocarriers through several administration routes. The main problems related to LMWHs have been surmounted, and improved efficiency may be achieved through the use of DDSs. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-05 2021-05-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/72485 |
url |
http://hdl.handle.net/1822/72485 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Patriota, Yuri B. G.; Chaves, Luíse L.; Gocke, Evren H.; Severino, Patricia; Soares, Mônica F. R.; Soares-Sobrinho, José L.; Souto, Eliana, Applied nanotechnologies in anticoagulant therapy: from anticoagulants to coagulation test performance of drug delivery systems. Applied Nano, 2(2), 98-117, 2021 2673-3501 10.3390/applnano2020009 https://www.mdpi.com/2673-3501/2/2/9 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
MDPI |
publisher.none.fl_str_mv |
MDPI |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132464266870784 |